依达拉奉联合神经节苷脂治疗急性脑梗死疗效观察

Curative effect of edaravone combined with ganglioside on patients with acute cerebral infarction

目的观察急性脑梗死患者应用依达拉奉联合神经节苷脂治疗的临床疗效。方法选取和平里医院神经内科2013年10月至2015年10月期间收治的急性脑梗死患者120例,按照随机数表法随机分为两组,每组60例,观察组给予依达拉奉联合神经节苷脂治疗,对照组给予单独依达拉奉治疗,均治疗2周后,比较两组患者的治疗效果以及美国国立卫生研究院卒中量表(NIHSS)评分、血清炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)以及C反应蛋白(CRP)]变化及不良反应情况。结果观察组患者的基本痊愈率及总有效率分别为16.67%(10/60)、86.67%(52/60),明显高于对照组的6.67%(4/60)、71.67%(43/60),差异均有统计学意义(P<0.05);观察组患者治疗后的NIHSS评分为(2.18±1.27)分,均显著低于治疗前的(5.23±2.32)分和对照组治疗后的(3.06±1.69)分,差异均有统计学意义(P<0.05);观察组患者治疗后的血清INF-α、IL-6以及CRP分别为(17.87±2.41)μg/L、(21.04±3.13)ng/L、(14.27±3.52)mg/L,均低于对照组的(22.47±4.26)μg/L、(29.52±5.95)ng/L、(19.49±2.58)mg/L,差异均有统计学意义(P<0.05);两组患者治疗期间均未出现肝肾损害等严重不良反应。结论依达拉奉联合神经节苷脂治疗急性脑梗死疗效较单独应用依达拉奉治疗明显提高,其可显著改善患者神经功能和血清炎症因子水平。

Objective To observe clinical curative effect of edaravone combined with ganglioside on patients with acute cerebral infarction.Methods A total of 120 cases of patients with acute cerebral infarction,who admitted to Department of Neurology of Hepingli Hospital from October 2013 to October 2015,were selected and divided into the observation group(treated with edaravone and ganglioside treatment) and the control group(only treated with edaravone therapy) according to the random number table method,with 60 cases in each group.Two weeks after treatment,the treatment effects,National Institutes of Health Stroke Scale(NIHSS) score,serum inflammatory factors [C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),and interleukin-6(IL-6)] and adverse reactions of the two groups were compared.Results The basic recovery rate and total effective rate of the observation group [16.67%(10/60),86.67%(52/60),respectively] were significantly higher than those of the control group [6.67%(4/60),71.67%(43/60),respectively](P<0.05);the NIHSS score after treatment in the observation group [(2.18±1.27) points] were significantly lower than that before treatment [(5.23±2.32) points] in the observation group and that after treatment in the control group [(3.06 ± 1.69) points](P<0.05).After treatment,the serum INF-α,IL-6 and CRP of the observation group[(17.87±2.41) μg/L,(21.04±3.13) ng/L,(14.27±3.52) mg/L,respectively] were significantly lower than those of the control group [(22.47±4.26) μg/L,(29.52±5.95) ng/L,(19.49±2.58) mg/L](P<0.05).There were no severe adverse reactions such as liver and kidney damage in the two groups during the treatment period.Conclusion Edaravone combined with ganglioside has higher curative effect than single application of edaravone in the treatment of acute cerebral infarction,which can significantly improve the neurological function and serum inflammatory factor levels.